Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

Áö¼Ó¼º ¿Ü·¡ º¹¸·Åõ¼® ȯÀÚ¿¡¼­ 9Á¾ÀÇ Ç÷û Á¾¾çÇ¥ÁöÀÚ¿¡ °üÇÑ ¿¬±¸ Nine Kinds of Tumor Markers in Patients on Continuous Ambulators Peritoneal Dialysis

´ëÇѽÅÀåÇÐȸÁö 1997³â 16±Ç 4È£ p.730 ~ 737
¼Ò¼Ó »ó¼¼Á¤º¸
À̼ºÃ¶/Seong Cheol Lee Á¤ÅñÕ/Á¤±Ç/ÇÏÁ¤ÈÆ/±è±â¿µ/±è¼ö¿Ï/±è³²È£/ÃÖ±âö/°­¿µÁØ/Jeong Taek Kyun/Jung Kwon/Jeong Hoon Ha/Ki Young Kim/Soo Wan Kim/Young Joon Kang/Nam Ho Kim/Chul Ki Choi

Abstract

¸ñÀû : ¸¸¼º½ÅºÎÀüÀº ´Ù¾çÇÑ ´ë»çÀÌ»óÀ» ÀÏÀ¸Å°°í ÀÌ·¯ÇÑ ´ë»çȯ°æÀÇ ÀÌ»óÀÌ ¿äµ¶Áõ½Ã Á¾
¾çÇ¥ÁöÀÚ Ç÷û ³óµµº¯È­¿¡ ±â¿©ÇÒ ¼öµµ ÀÖ´Ù. ÀúÀÚµéÀº Áö¼Ó¼º ¿Ü·¡ º¹¸·Åõ¼®(CAPD)ÁßÀÎ
ȯÀÚ¿¡¼­ Á¾¾çÇ¥ÁöÀÚµéÀÇ Ç÷û³óµµ, ¾ç¼º·ü ¹× ÃøÁ¤Ä¡ÀÇ À¯¿ë¼ºÀ» ¾Ë¾Æº¸°íÀÚ º» ¿¬±¸¸¦ ½Ã
ÇàÇÏ¿´´Ù.
¹æ¹ý : ¾Ï ÁúȯÀÇ ÁõÈÄ ¹× Áõ°Å°¡ ¾ø´Â 46¿¹ÀÇ CAPD ȯÀÚµéÀÇ Ç÷û¿¡¼­ 9Á¾ÀÇ Á¾¾çÇ¥Áö
ÀÚ carcinoembryonic antigen(CEA), squamous cell carcinoma-related antigen(SCC),
cytokeratin fragment(CYFRA) 21-1, carbohydrate antigen(CA) 125, CA 19-9 ¹× ¥á
-feto-protein(AFP), prostate specific antigen(PSA), human chorionic gonadotropin(hCG),
CA 72-4¸¦ ÃøÁ¤ ÈÄ Á¤»ó ½Å±â´ÉÀ» °¡Áø 68¿¹ÀÇ ´ëÁ¶±º°ú ºñ±³ ºÐ¼®ÇÏ¿© ´ÙÀ½ÀÇ °á°ú¸¦ ¾ò
¾ú´Ù.
°á°ú :
1) CEAÀÇ Ç÷û Æò±ÕÄ¡´Â ´ëÁ¶±º¿¡ ºñÇØ CAPD±º¿¡¼­ À¯ÀÇÇÏ°Ô ³ô¾ÒÀ¸¸ç(p<0.001), ¾ç¼º
·üÀº 50.0%À̾ú´Ù. SCCÀÇ Ç÷û Æò±ÕÄ¡´Â ´ëÁ¶±º¿¡ ºñÇØ CAPD±º¿¡¼­ À¯ÀÇÇÏ°Ô ³ô¾ÒÀ¸¸ç
(p<0.001), ¾ç¼º·üÀº 75.0%À̾ú´Ù. CYFRAÀÇ Ç÷û Æò±ÕÄ¡´Â ´ëÁ¶±º¿¡ ºñÇØ CAPD±º¿¡¼­ À¯
ÀÇÇÏ°Ô ³ô¾ÒÀ¸¸ç(p<0.001), ¾ç¼º·üÀº 88.6% À̾ú´Ù. CA 125ÀÇ Ç÷û Æò±ÕÄ¡´Â ´ëÁ¶±º ¹×
CAPD±º¿¡¼­ °¢°¢ 17.9¡¾11.7U/mL, 31.2¡¾40.8U/mL·Î CAPD±º¿¡¼­ À¯ÀÇÇÏ°Ô ³ô¾ÒÀ¸¸ç
(p<0.001), ¾ç¼º·üÀº 21.6%À̾ú´Ù. CA 19-9ÀÇ Ç÷û Æò±ÕÄ¡´Â ¸¸¼º½ÅºÎÀü±º¿¡¼­ Á¤»ó¹üÀ§¿¡
¼ÓÇÏ¿´À¸³ª ´ëÁ¶±ºÀÇ Æò±ÕÄ¡¿¡ ºñÇØ À¯ÀÇÇÏ°Ô ³ô¾ÒÀ¸¸ç(.p<0.01), ¾ç¼º·üÀº 20.0%À̾ú´Ù.
2) AFP, PSA, hCG ¹× CA 72-4ÀÇ Æò±Õ Ç÷ûġ´Â ´ëÁ¶±º°ú ºñ±³ÇÏ¿© CAPD±º¿¡¼­ À¯ÀÇ
ÇÑ Â÷ÀÌ´Â ¾ø¾úÀ¸¸ç, CAPD ±º¿¡¼­ ¾ç¼º·üÀº °¢°¢ 2.2%, 3.8%, 8.3% ¹× 4.0%À̾ú´Ù.
°á·Ð : ÀÌ»óÀÇ °á°ú´Â CAPD ȯÀÚ¿¡¼­ CEA, SCC, CYFRA 21-1, CA 125 ¹× CA 19-9´Â
Á¤»óÀΰú ºñ±³ÇÏ¿© ºñ±³Àû ³ôÀº À§¾ç¼º·üÀ» º¸¿©, Á¤»óÄ¡·Î ¼³Á¤µÈ »óÇÑÄ¡·Î´Â ¾Ç¼ºÁ¾¾çÀÇ
Áø´Ü ¹× ÃßÀû°Ë»ç·Î´Â À¯¿ëÇÏÁö ¸øÇÔÀ» ¾Ë ¼ö ÀÖ¾ú´Ù. µû¶ó¼­ ¸¸¼º½ÅºÎÀü ȯÀÚ¿¡¼­´Â »õ·Î
¿î »óÇÑÄ¡°¡ ¼³Á¤µÇ¾î¾ß ÇÒ °ÍÀ¸·Î »ç·áµÈ´Ù. ¹Ý¸é AFP, PSA, hCG ¹× CA 72-4´Â Ç÷û Æò
±ÕÄ¡ ¹× ¾ç¼º·ü¿¡ ÀÖ¾î ´ëÁ¶±º°£¿¡ À¯ÀÇÇÑ Â÷ÀÌ°¡ ¾ø¾î Á¤»óÀο¡¼­»Ó¸¸ ¾Æ´Ï¶ó CAPD ȯÀÚ
¿¡¼­µµ Àû¿ëµÈ À¯¿ëÇÑ Á¾¾çÇ¥ÁöÀÚ·Î ÀÌ¿ëµÉ ¼ö ÀÖÀ½À» ½Ã»çÇÑ´Ù.
#ÃÊ·Ï#
Tumor markers have been clinically used to monitor the progression of various
tumors or to assess their response to therapy. We studied the effects of continuous
ambulatory peritoneal dialysis(CAPD) on the serum levels of nine tumor markers;
carcinoembryonic antigen(CEA), squamous cell carcinoma-related antigen(SCC), CYFRA
21-1, CA(carbohydrate antigen) 125, CA 19-9, a-fetoprotein(AFP), prostate specific
antigen(PSA), human chorionic gonadotropin (hCG) and CA 72-4.Serum tumor markers
were measured in 68 persons without chronic renal failure(CRF) as controls, and 46
stable CAPD patients who did not present any evidences of neoplasia.
The results were as followings:
1) Serunl AFP, PSA, hCG and CA 72-4 levels were almost within normal limits in
the peritoneal dialysis similar to normal control groups; positive values were 2.2%, 3.8%,
8.3% and 4.0%, respectively.
2) Serum tumor markers, which were raised in the peritoneal dialysis compared to
normal controls, include; CEA (5.29¡¾3.6 vs. 1.42¡¾1.0, P<0.001); SCC(3.90¡¾5.57 vs. 0.9¡¾
1.1, P<0.01); CYFRA 21-1 (5.45¡¾3.2 vs. 1.80¡¾1.5, P<0.001); CA 125 (31.22¡¾40.8 vs.
17.91¡¾11.7, p<0.001); CA 19-9 (24.25¡¾18.3 vs. 14.41¡¾12.1, p<0.01). Raised CEA, SCC,
CYFRA 21-1, CA 19-9 and CA 125 levels were detected 50%, 75%, 88.6%, 21.6% and
20.0% of peritoneal dialysis patients.
In conclusion, serum levels of CEA, SCC, CYFRA 21-1, CA 19-9, CA 125 cannot be
used as prognostic indicators for patients with malignancy while undergoing peritoneal
dialysis treatment, but the other tumor markers such as AFP, PSA, hCG and CA 72-4
can be used as reliable tumor markers for patients of peritoneal dialysis similar to
normal healthy people.

Å°¿öµå

Tumor marker; Chronic renal failure; Continuous Ambulatory Peritoneal Dialysis(CAPD);

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS